COMPASS Pathways (NASDAQ:CMPS) Earns “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of COMPASS Pathways (NASDAQ:CMPS) in a research report report published on Monday morning, Benzinga reports.

Several other research analysts have also weighed in on CMPS. Royal Bank of Canada began coverage on shares of COMPASS Pathways in a research report on Tuesday, July 23rd. They set an outperform rating and a $23.00 target price on the stock. HC Wainwright reaffirmed a buy rating and issued a $120.00 price objective on shares of COMPASS Pathways in a research note on Friday, August 23rd. Finally, Canaccord Genuity Group decreased their target price on COMPASS Pathways from $50.00 to $48.00 and set a buy rating on the stock in a research report on Friday, August 2nd. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, COMPASS Pathways has a consensus rating of Buy and an average price target of $47.40.

COMPASS Pathways Price Performance

Shares of CMPS opened at $6.78 on Monday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 12.03 and a current ratio of 12.03. COMPASS Pathways has a fifty-two week low of $5.01 and a fifty-two week high of $12.75. The firm has a 50-day simple moving average of $7.13 and a 200-day simple moving average of $7.96. The company has a market capitalization of $463.62 million, a price-to-earnings ratio of -2.86 and a beta of 2.27.

COMPASS Pathways (NASDAQ:CMPS) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.03). During the same quarter in the prior year, the firm earned ($0.62) earnings per share. On average, equities research analysts anticipate that COMPASS Pathways will post -2.35 earnings per share for the current year.

Institutional Trading of COMPASS Pathways

Institutional investors have recently added to or reduced their stakes in the business. Jump Financial LLC acquired a new position in COMPASS Pathways during the 4th quarter worth approximately $371,000. Quest Partners LLC acquired a new stake in COMPASS Pathways during the 4th quarter valued at $33,000. Affinity Asset Advisors LLC acquired a new stake in shares of COMPASS Pathways during the fourth quarter valued at about $4,812,000. PFM Health Sciences LP increased its position in shares of COMPASS Pathways by 540.7% during the fourth quarter. PFM Health Sciences LP now owns 338,761 shares of the company’s stock worth $2,964,000 after acquiring an additional 285,890 shares during the last quarter. Finally, Chesapeake Capital Corp IL acquired a new position in shares of COMPASS Pathways in the first quarter worth about $189,000. 46.19% of the stock is owned by hedge funds and other institutional investors.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.